Similarly, upon comparison between primary tumors and patient-derived xenograft models (PDXs), high-VAF mutations tended to remain stable and not change, yielding a similar heterogeneity of KRAS mutant alleles in both primary tumor samples and in subsequent tumors passaged and grown as mouse xenografts. Here, KRAS is linked to neoplasm.